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RESUMO
PLURIPOTÊNCIA E REPROGRAMAÇÃO CELULAR
O desenvolvimento em mamíferos começa após a fecundação e singamia dos 
genomas haplóides. O recém formado zigoto passa por múltiplas divisões 
celulares e torna–se um embrião composto de células pluripotentes, que darão 
origem a todos os tecidos encontrados nos animais adultos. As linhagens de 
células–tronco embrionárias (CTE) são cultivos ex vivo de células pluripotentes 
provenientes de embriões. As CTE oferecem novas oportunidades para 
investigar o desenvolvimento em mamíferos, para criar novos modelos de 
doenças humanas, e possivelmente para oferecer células para transplantes. O 
nascimento de animais clonados pela transferência nuclear de células somáticas 
para ovócitos demonstrou a reversibilidade da diferenciação celular, um 
processo denominado reprogramação celular. Outros métodos para obtenção 
de células reprogramadas indiferenciadas a partir de núcleos somáticos foram 
descritos, baseados na fusão celular ou na expressão exógena de determinados 
genes. A reprogramação celular permitiu o isolamento de células pluripotentes 
de pacientes para investigação da etiologia de doenças humanas e prospeção 
de novos medicamentos. Apesar do progresso monumental no entendimento 
do desenvolvimento inicial em mamíferos, a complexidade da pluripotência 
e reprogramação celular ainda são pouco entendidos. Esta revisão tem como 
objetivo descrever as principais descobertas nestes campos científicos, citar 
limitações técnicas e biológicas destas linhas de pesquisas, e prover possíveis 
soluções para contornar tais dificuldades. 
Termos para indexação: células tronco, epigenética, clonagem.
ABSTRACT
PLURIPOTENCY AND CELLULAR REPROGRAMMING
Mammalian development commences after fertilization and syngamy of  
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haploid genomes. The newly formed zygote faces multiple cell divisions 
and becomes an embryo composed of  pluripotent cells, that will give rise 
to all cell types found in adult animals. Embryonic stem (ES) cell lines are 
ex vivo cultures of  pluripotent cells from early embryos. ES cells offer new 
possibilities to dissect mammalian development, to model human disease, and 
to potentially provide cells for transplantation. The birth of  cloned animals 
after somatic cell nuclear transfer to oocytes demonstrated the reversibility 
of  cellular differentiation, a process denominated cellular reprogramming. 
Other methods to obtain reprogrammed undifferentiated cells from somatic 
nuclei have been described, based on cell fusion and ectopic expression of  
key genes. Cellular reprogramming allowed derivation of  patient–specific 
pluripotent cells for investigations of  disease etiologies and prospection for 
new therapeutics. Despite monumental progress in understanding on the 
nature of  mammalian early development, the complexity of  pluripotency 
and cellular reprogramming are still poorly understood. This review aims to 
describe major findings in these research fields, outline technical and biological 
limitations to this research, and provide possible alternatives to overcome 
them. 
Index terms: stem cells, epigenetics, cloning.
1. eMbryonic DevelopMenT
The process of  fertilization marks the encounter of  two highly specialized cell–
types: sperm cells and oocytes. After the sperm cell enters the oocyte cytoplasm, its 
nucleus is engaged in an intense event of  remodelling, in order to convert the highly 
condensed, transcriptionally inactive spem cell nucleus into a transcriptionally and 
replication competent haploid genome. Since the genome at the DNA level remains 
unchanged, reprogramming is not genetic, but epigenetic in nature (e.g. histone 
marks and DNA methylation). This remodelling is achieved by replacing protamines 
by acetylated histones and genome–wide DNA demethylation (Oswald et al., 2000; 
Mayer et al., 2000; Feng et al., 2010). Remarkably, the oocyte genome is protected from 
epigenetic remodelling by trans–acting proteins STELLA (Nakamura et al., 2007), 
ZFP57/KAP1 (Quenneville et al., 2011), and possibly other unidentified factors. 
After completion of  DNA replication on both male and female pro–nuclei, 
they fuse and the first embryonic cell division takes place (Figure 1) (Li et al., 2010). 
Several rounds of  cell division are followed, accompanied by continuous genome–
wide reprogramming, but in a passive fashion (Feng et al., 2010; Inoue & Zhang, 
2011). At the funcional level, blastomeres of  early embryos are totipotent, namely, 
have the potential to form all fetal and placental tissues. This fact was formely 
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demonstrated in several species by live births from isolated blastomeres (Moore 
et al., 1968; Willadsen, 1980). Although the genome is facing an intense structural 
remodeling during these initial cell divisions, transcription is not detected from 
most genes (Li et al., 2010). Development is controlled at this point by the oocyte 
cytoplasm, and when the embryonic genome becomes active, the embryo faces a 
progressive transition period of  development control that ends around the time of  
implantation (Stitzel & Seydoux, 2007; Li et al., 2010). 
After embryonic genome activation, the embryo embarks in the first process 
of  cellular differentiation (Figure 1). The whole embryo begins to compact at the 
morula stage: outer cells become flat and polarized, while the inner cells remain 
unchanged (Li et al., 2010; Cockburn & Rossant, 2010). Shortly after, the embryo 
starts to acumulate liquid and forms a cavity denominated blastocele. At this time 
point, the embryo now denominated blastocyst, holds two morphologically and 
functionally distinct cell types: trophoblast (will form all placenta tissues) and the 
inner cell mass (ICM), a pluripotent cell population. Pluripotency is defined as 
the ability to give rise to all cell types that make up the body of  the adult animal 
(Cockburn & Rossant, 2010). Moreover, the ICM will segragate into two distinct 
populations: hypoblast or primitive endoderm and the epiblast (Rossant, 2008). 
Hyploblast cells form the yolk sac, and epiblast cells will give rise to fetal somatic 
cell types and primordial germ cells (PGC). The proliferating PGC pool migrates to 
genital ridges of  the midgestation fetus, and differentiate to sperm cells or oocytes, 
depending on embryo gender (Figure 1).
2. eMbryonic STeM cellS
Embryonic stem (ES) cells are pluripotent cell lines stablished from ICM cultures 
under specific in vitro conditions (Figure 1) (Evans & Kaufman, 1981; Martin, 1981; 
Thomson et al., 1995, 1998; Solter, 2006). If  properly cultured, ES cell lines can 
be propagated indefinitely, without signs of  senescence or differentiation (Smith, 
2001). When introduced into blastocysts, mouse and rat ES cells demonstrate their 
capacity to colonize somatic tissues and the germline (Bradley et al., 1984; Smith, 
2001; Buehr et al., 2008; Li et al., 2008). A more instrigent version, the tetraploid 
embryo complementation assay, further demonstrated the capacity of  ES cells to 
solely form the mouse fetus (Nagy et al., 1993; Smith, 2001; Eggan et al., 2004; 
Stadtfeld et al., 2010). Due to ethical constrains, human ES cells pluripotency in vivo 
is assayed by injection of  ES cells in immuno–compromised mice, also known as 
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Figure 1. — Mouse development and pluripotent stem cell derivation.
the teratoma assay (Lensch et al., 2007). Moreover, this tumor can be inferred if  it 
contains ES–derived tissues of  all three embryonic germ layers. 
Concomitant with firts reports of  ES cell derivation in the mouse, several groups 
succeeded using homologous recombination to manipulate the mouse genome at 
precise loci (Capecchi, 1989). When combined, these two technologies became an 
efficient approach to modify the mouse genome in order to investigate gene function 
(Capecchi, 1989, 2005; Adams & Van Der Weyden, 2008). 
Several genes, most notably transcription factors, have been described as 
pluripotency genes: Oct4, Sox2, Stat3, Nanog, Sall4, Ronin, Nr5a2, among others 
(Nichols et al., 1998; Niwa et al., 2000; Chambers et al., 2003; Mitsui et al., 2003; 
Welstead et al., 2008). Transcription factors are DNA–binding proteins that modulate 
transcription of  their target genes by recruitment of  activation and/or repression 
complexes to regulatory sequences such as promoters and enhancers (Lee & Young, 
2000; Hobert, 2008). Pluripotency genes are divided in two subclasses: genes that 
maintain the undifferentiated state in embryos and ES cells (Oct4, Sox2, Nanog, 
Sall4), and self–renewal genes (Stat3, c–Myc, Klf4). Self–renewal is defined as the 
ability of  an ES cell to divide and form two daughter ES cells. In the mouse, ES 
self–renewal is activated by addition of  leukemia inhibitory factor (LIF) to culture 
media, which induces Janus Kinase / Stat3 signalling (Williams et al., 1988; Niwa et 
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al., 1998; Burdon et al., 2002; Boiani & Schöler, 2005). However, human and monkey 
ES cells relie on ERK signalling activated by bFGF to avoid differentiation in culture 
(Amit et al., 2000). These discoveries led to a widely accepted hypothesis that ES cells 
were an in vitro culture artifact, and their functional correspondence to a defined cell 
population in embryos as an unlikely possibility (Hansson et al., 2007). Remarkably, 
the supression of  differentiation stimuli (ERK and GSK3 signalling pathways 
– 2i condition) allowed mouse ES cells to self–renewal in absence of  LIF/Stat3 
signalling activation (Ying et al., 2008). These facts demonstrates that pluripotent 
cells in early embryos and ES cells hold an intrinsic ability to self–renewal, but are 
guided for differentiation during development (Ying et al., 2008; Nichols et al., 2009). 
Furthermore, use of  2i condition was successfull at deriving much antecipated rat 
ES cell lines (Buehr et al., 2008; Li et al., 2008).
The determination of  binding sites of  pluripotency genes such as Oct4, Sox2, and 
NANOG at genomic level are undercovering cellular mechanisms by which these 
genes contibute to the maintainace of  pluripotency (Boyer et al., 2005; Loh et al., 
2006; Jaenisch & Young, 2008; Kim et al., 2008a). Alternatively, physically associated 
proteins to pluripotency genes such as NANOG have been identified, and further 
characterized the pluripotency gene repertoire (Wang et al., 2006). Collectively, these 
reports described the cooperation between multiple genes in order to establish 
pluripotency and avoid activation of  differentiation inducing factors (Boyer et al., 
2005, 2006; Wang et al., 2006). Due to the fast growing amount of  genome–wide 
projects, systems biology approaches will be extremely useful to integrate fast–
growing number of  data sets and provide a broader understading of  cellular states 
and their transitions (Lu et al., 2009; Macarthur et al., 2009). 
The epigenetic basis of  pluripotency is focus of  intense research (Jaenisch & 
Young, 2008). DNA methylation is dispensable for ES cells self–renewal (Tsumura 
et al., 2006), but is required for their differentiation (Jaenisch, 1997). ES cells relie on 
histone methylation (H3k9me2/3 and H3K27me3) for gene repression (Boyer et al., 
2006a; Lee et al., 2006). Transcription factors with important roles in development 
are marked in ES cells by both activating histone methylation (H3K4me3) and 
repressive marks (H3k9me2/3 and H3K27me3), a chromatin state termed 
bivalent domain (Azuara et al., 2006; Bernstein et al., 2006). This discovery was 
surprising, because chromatin states were always captured as carrying “activating” 
or “repressive” epigenetic marks, but never both types. The interpretation is that 
bivalent domains poise genes for rapid activation or repression following instructive 
Anais da Academia Pernambucana de Ciência Agronômica, vols. 8 e 9, p.138-168, 2011/2012.
143M.T. MOURA
cellular differentiation signals (Boyer et al., 2006b). In accordance with this model, 
after differentiation, bivalent domains found in ES cells are generally resolved as 
fully repressed genes or actively transcribed genes (Mikkelsen et al., 2007). Other 
epigenetic components of  bivalent domains have been found, suggesting a more 
complex regulation of  this chromatin state. Bivalent domains were also found in 
early embryos and somatic cells (Mikkelsen et al., 2007; Vastenhouw et al., 2010), 
demonstrating the potential of  ES cells to underscore epigenetic regulatory 
mechanisms. 
It became evident over the years that pluripotency is not one stable cellular state. 
Variations at molecular and functional levels have been observed across pluripotent 
cultures, within ES cell lines, and even in individual cells (Chambers et al., 2007; 
Hayashi et al., 2008; Toyooka et al., 2008; Han et al., 2010). Despite intrinsic functional 
fluctuations in pluripotent states, a pronounced difference in developmental potency 
was observed between mouse and human ES cells (Nichols & Smith, 2009). An 
important finding came from mouse pluripotent cultures established using human 
ES–specific conditions. These lines, coined Epiblastic stem cells (EpiSC), hold 
morphpological, transcriptional, and functional properties that resembled more 
closely human ES cells than mouse ES counterparts (Brons et al., 2007; Tesar et al., 
2007). This lead to the concept that pluripotency states are to some degree dependent 
on culture conditions, that guide undifferentated cells to cycle in a determined 
cellular state (Nichols & Smith, 2009; Hanna et al., 2010a). Moreover, our growing 
understanding of  these differences are coming from demonstrations that precise 
changes in culture conditions (2i culture) and ectopic expression of  pluripotency 
genes (e.g. Stat3, Nr5a2, Klf4) can convert mouse EpiSC in ES cells (Hanna et al., 
2010a), and human ES or iPS into “Naive” pluripotent cells, that resemble mouse 
ES cells (Buecker et al., 2010; Hanna et al., 2010b).
Genome–wide epigenetic and transcriptional analysis of  pluripotent cell 
subpopulations with contrasting functional properties (Chambers et al., 2007; 
Hayashi et al., 2008; Toyooka et al., 2008; Han et al., 2010), may aid dissection of  
molecular determinants of  pluripotency and further describe molecular signatures 
for these discrete pluripotent states. 
3. cellular reprograMMing by nuclear TranSfer
Nuclear transfer (NT) was developed in order to test if  cellular differentiation 
is acompanied by loss of  genetic content (Briggs & King, 1952; Solter, 2000). The 
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introduction of  somatic cells into enucleated oocytes was capable of  recapitulating 
development to term, with some clones surviving to adulthood, demonstrating 
nuclear equivalency between adult cells (Figure 2) (Gurdon et al., 1958; Wilmut et al., 
1997). More recently, cloning technology became an usefull technology for a broad 
range of  applications: for scientific research (Eggan et al., 2004; Hochedlinger et al., 
2004), to generate transgenic animals (Schnieke et al., 1997; Kuroiwa et al., 2004), to 
replicate desired genomes (Loi et al., 2001), to produce advantageous mouse models 
(Kirak et al., 2010), among other applications.
Figure 2. — Cellular reprogramming in mammals.
The therapeutic potential of  NT was demonstrated by isolation of  ES cells from 
cloned embryos (NT–ES cells), directed differentiation of  these cells to a specific cell 
type, tranplantation in animal models, followed by amelioration of  disease symptoms 
(Rideout et al., 2002; Lanza et al.,  2004; Barberi et al., 2003). This approach, known 
as therapeutic cloning, has potential to generate unlimited numbers of  genetically 
matched cells from patients for transplantation, avoiding graft immune rejection 
(Solter, 2006). These patient–specific cells can also be useful to establish in vitro 
disease models and drug screening (Solter, 2006). However, human and non–human 
primate NT research has progress so far at a slower pace than other mammalian 
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species, and only rhesus monkey NT–ES cell lines have been described (Byrne et al., 
2007). 
Cellular reprogramming by NT represents an enormous biological challenge: the 
oocyte needs to remodel a somatic nucleus to an epigenetic state similiar to a zygote. 
Not surprisingly, cloning by NT is an inneficient process (Moura et al., 2008; Moura, 
2011). No more than 5% of  cloned embryos develop to term, and around 50% 
of  cloned infants reach adulthood (Wilmut et al., 2002). Similar cloning efficiencies 
were obtained from vertebrate and invertebrate animals, ruling out species–specific 
technical or biological limitations (Gurdon et al., 1958; Wilmut et al., 1997, 2002; Lee 
et al., 2002; Haigh et al., 2005). Some investigations have found genetic instability 
after NT (Simerly et al., 2003; Shi et al., 2004; Mizutani et al., 2012), but incorrect 
epigenetic resetting of  the genome accounts for the majority, if  not all causes of  
development losses (Kang et al., 2001; Santos et al., 2003). Moreover, it can not be 
ruled out that these genetic alterations in animal cloning have an epigenetic basis 
(Gaudet et al., 2003). 
The remodelling or reprogramming of  sperm cells by oocytes is a precise, 
and well orchestrated process. Mammalian sperm genomes are mostly packed 
by protamines and DNA methylation (Miller et al., 2010). Curiously, around 4% 
of  nucleosomes found in somatic cells are found in human spermatozoa and 
are not randomly distributed across the genome: coding sequences of  imprinted 
genes, microRNA, and hox genes are enriched for nucleosome–bound DNA 
(Hammoud et al., 2009). In contrast, somatic cells relie on coorporation between 
DNA methylation and repressive histone methylation in order to stably maintain 
their cellular phenotype (Cedar & Bergman, 2009). Collectively, somatic cells lack 
instructive signals for remodelling (such as protamines), carry multiple regulatory 
mechanisms to avoid activation of  pluripotency genes (Feldman et al., 2006), and 
possess mechanisms that reinforce their somatic cell fate in cloned embryos (e.g. 
histone variant H3.3) (Ng & Gurdon, 2008). These biological barriers to somatic 
nuclei remodelling are supported by several evidences of  partial reprogramming: 
incomplete reactivation of  pluripotency genes (Boiani et al., 2002; Bortvin et al., 
2003), precocious activation of  donor cell–especific genes (Ng & Gurdon, 2005, 
2008), DNA and histone hypermethylation in cloned embryos or somatic and extra–
embryonic tissues of  cloned fetuses (Dean et al., 2001; Reik et al., 2001; Rideout et al., 
2001; Yang et al., 2007). 
The spectrum of  placentation problems is considered a particular bottleneck 
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for mammalian cloning, due to the fact that most pregnancies are lost around the 
time of  maternal recognition and implantation (Yang et al., 2007). However, the 
generation of  mouse embryos with contribution of  reprogrammed cells limited to 
placental lineages resulted in conflicting results (Miki et al., 2009; Lin et al., 2011). 
Similar functional assessments of  NT–derived placentas on larger species (e.g. 
sheep, bovine) might solve this question. Remarkably, mouse NT–ES cells are 
indistinguishable from ES cells derived from fertilized embryos at both molecular 
and functional levels (Brambrink et al., 2006; Wakayama et al., 2006).
Multiple procedures have been tested for improving cloning efficiency: embryo 
re–cloning (Galli et al., 1999), serial cloning (Polejaeva et al., 2000), two–step cloning 
(Hochedlinger & Jaenisch, 2002), NT embryo aggregation (Boiani et al., 2003), and 
treatment of  donor cells (chromatin modifyers, heating, or cellular extracts) (Loi 
et al., 2002; Sullivan et al., 2004). The overall limited increase in reprogramming 
efficiency by these “intuitive” methods call for research on targeted approaches 
to raise cloning efficiency. The substantial increase in mouse cloning efficiency by 
ablation of  Xist expression in both male and female somatic cells or NT embryos is 
in accordance with this hypothesis (Inoue et al., 2010; Matoba et al., 2011). 
The phenomenon of  cellular reprogramming has been extensively explored 
using cloning technology, but the mechanism at the molecular level remains largely 
enigmatic (Hochedlinger & Jaenisch, 2006). This scenario is mostly due to limited 
suitability of  NT reprogramming system for biochemical analysis: oocytes are scarce, 
difficult for genetic manipulation; NT is labor intensive, technically challeging, and 
yields embryos at small numbers. 
Future research should focus on genome–wide studies using recently developed 
protocols for small biological samples (Adli et al., 2010), since research to scale–
up NT embryo production have met little success (Moura, 2011). The analysis of  
DNA methylation and histone modification dynamics at high resolution during 
embryonic development and after NT will be extremely informative (Smith et al., 
2012). Attention should be focused on early reprogramming events, when intense 
chromatin dynamics are found (Kikyo et al., 2000). Direct comparison of  chromatin 
remodelling using different templates (sperm cell, oocyte, and somatic nucleus) 
should shed some light on limiting factors to reprogramming, core reprogramming 
components, and combinatory interaction between epigenetic mechanisms. More 
detailed information on epigenetic reprogramming by oocytes will refine future 
approaches to increase reprogramming efficiency. 
Anais da Academia Pernambucana de Ciência Agronômica, vols. 8 e 9, p.138-168, 2011/2012.
147M.T. MOURA
4. cellular reprograMMing by cell fuSion 
Based on the notion that oocytes contain factors to reprogram somatic cells to 
totipotency, ES cells were tested as an alternative source to convert differentiated 
nuclei into pluripotent cells (Miller & Ruddle, 1976; Tada et al., 2001). After cell 
fusion and progression through mitosis, ES cell nuclear factors interact with the 
somatic cell genome, resulting in a tetraploid undifferentiated cell (Tada et al., 2001; 
Egli et al., 2008) (Figure 2). This strategy was used to demonstrate that human 
somatic cells are also ameneable to cellular reprogramming (Cowan et al., 2005; Yu 
et al., 2006). Cell fusion has also gained attention as an attractive method to identify 
cellular components required for reprogramming (Hochedlinger & Jaenisch, 2006; 
Silva et al., 2006; Ma et al., 2008; Pereira et al., 2008, 2010; Bhutani et al., 2010).
Some technical and biological issues limit potential applications of  cell fusion 
for addressing reprogramming: low fusion yields, presence of  an extra genome (ES 
cell nucleus), and possible epigenetic and functional heterogeneity in cells under 
reprogramming (Pralong et al., 2006; Skelley et al., 2009). Cell fusion–mediated 
reprograming protocols relie on chemical membrane fusion or electrofusion of  cell 
suspensions to generate somatic–ES cell hybrids (Tada et al., 2001; Cowan et al., 2005). 
Low fusion rates are generally due to low and random cell–cell pairing for fusion. The 
development of  a microfluidic device allowed high cell pairing and fusion between 
different cell types, and reprogrammed cells could be obtained at large numbers 
(Skelley et al., 2009). The presence of  an extra genome in hybrid cells complicates 
the investigation of  epigenetic remodelling of  somatic cells after cell fusion. An 
usefull approach would be to use genetically distinct genomes to provide somatic 
and ES cell populations for fusion, and by DNA sequencing, identify the source 
of  analysed DNA or chromatin samples (Cowan et al., 2005; Noggle et al., 2011). 
The epigenetic heterogenety of  cells undergoing reprogramming is probably due, at 
least in part, to increasing stochastic noise as cells progressively lose stable somatic 
cell transcriptional program and acquires a pluripotency transcriptional signature 
(Pujadas & Feinberg, 2012). These hybrid cell populations could be fractioned by 
selective markers (e.g. cell surface markers), in order to identify different stages or 
cell populations during reprogramming. Alternatively, single–cell analysis could also 
be used to estimate this reprogramming heterogeneity. 
The main functional limitation of  reprogrammed cells by fusion is the extra 
chromosome set in resulting cells (Pralong et al., 2006). Although 4n ES–like cells 
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may hold some therapeutic potential (Sullivan & Eggan, 2006), removal of  ES 
genome will still be necessary to demonstrate complete reprogramming after cell 
fusion (Yamanaka, 2007). Investigations aiming to enucleate ES cells, mainly by 
centrifugation, have been unsucessful (Do & Schöler, 2004;  Hasegawa et al., 2010). 
Some reports have claimed that reprogramming–competent enucleated ES cells were 
obtained after centrifugation, but evidence of  complete somatic cell reprogramming 
is still lacking (Pralong et al., 2005; Strelchenko et al., 2006; Du et al., 2011). The 
targeted deletion of  single chromosomes was achieved in ES cells (Matsumura et al., 
2007), but the method seems impractical for enucleation of  several chromosomes. 
Alternatives methods based on chemical enucleation may hold potential to enucleate 
ES cells while maintaining reprogramming ability (Moura, 2011). 
An important biological issue should be resolved before further ES cell 
enucleation efforts: the determination of  reprogramming kinetics following cell 
fusion (Egli et al., 2008; Han et al., 2008). If  multiple cell divisions are required for 
completion of  reprogramming, than current ES cell enucleation methods may not 
be suitable, and approaches to deliver additional loads of  reprogramming factors 
after ES cell enucleation may need to be designed. 
Technical variations for cell fusion reprogramming were developed aiming 
to avoid the induction of  tetraploidy: use of  mitotic ES cell nuclear/cytoplasmic 
extracts incubation with permeabilized somatic cells or whole transcriptome transfer 
to differentiated nuclei (Taranger et al., 2005; Sul et al., 2009). However, these alternate 
methods still need to demonstrate that cells obtained are truly reprogrammed.
5. cellular reprograMMing by DefineD facTorS
The enthusiasm brought by therapeutical evidence of  both reprogramming 
and ES cell technologies in animal models was somewhat diminished by ethical, 
logistical, and technical hurdles found in human NT research. Even if  successful, 
therapeutic cloning would probably be an umpractical technology in clinical settings. 
Based on these facts, it became a concensus that methods to reprogram cells to a 
pluripotent state without the use of  oocytes should be persued (Hochedlinger & 
Jaenisch, 2006). 
The road to cellular reprogramming without oocytes seemed very long: 
reprogramming mechanisms were poorly investigated; the understanding of  
pluripotency and epigenetic mechanims were far from complete.  
A major advance came from one of  the first attempts to reprogram cells without 
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oocytes: ES–like cells were obtained by exogenous expression of  24 pluripotency 
genes in mouse fibroblasts (Takahashi & Yamanaka, 2006). It became evident 
from this report that only four genes were responsible for this astonishing cellular 
conversion: Oct4, Sox2, Myc, and Klf4 (Figure 2). However, molecular and functional 
evaluations demonstrated that these cells, coined induced pluripotent stem (iPS) 
cells, were not fully reprogrammed (Takahashi & Yamanaka, 2006). Notwithstanding, 
these evidences proved the potential of  cellular reprogramming by defined factors. 
Refinements in selection methods resulted in mouse iPS cells that better 
resembled ES couterparts in morphology, growth characteristics, gene expression 
and epigenetic profiles, differential potential (in vitro and in vivo), and germline 
transmission competence (Maherali et al., 2007;  Okita et al., 2007; Wernig et al., 
2007; Yamanaka & Blau, 2010). Human cells  from healthy donors or patients were 
also ameneable to reprogramming by defined factors (Takahashi et al., 2007; Yu et 
al., 2007; Dimos et al., 2008; Lowry et al., 2008; Park et al., 2008a,b; Cherry & Daley, 
2012). 
Several reports have demonstrated that mouse iPS–derived cells rescue animal 
disease models (Hanna et al., 2007; Wernig et al., 2008; Xu et al., 2009). Human patient–
specific iPS cell lines can differentiate to disease relevant cells at unlimited numbers 
(Dimos et al., 2008), establish human in vitro disease models, and recapitulate disease 
phenotypes (Saha & Jaenisch, 2009; Cherry & Daley, 2012). The most promising 
iPS–based disease models to date are monogenic diseases with high penetrance, with 
early childhood onset or during development (Cherry & Daley, 2012). An evident 
exception is the recapitulation of  schizophrenia associated neuronal phenotypes 
(Brennand et al., 2011). A caution note came from the demonstration that iPS cells 
from autologous skin can generate immunogenic differentiated progeny, probably 
due to incomplete reprogramming (Zhao et al., 2011).
A major current research objective is to determine if  there are any molecular 
or functional differences between ES and iPS cells. The birth of  mice derived from 
iPS using the tetraploid embryo complementation assay demonstrates that these 
cells are compatible with the most rigorous functional test for pluripotency (Boland 
et al., 2009; Kang et al., 2009; Zhao et al., 2009). However, several differences at the 
molecular level have been identified: DNA methylation profiles (Kim et al., 2010; 
Lister et al., 2011), mutation rates (Gore et al., 2011; Hussein et al., 2011), skewed 
in vitro differentiation (Kim et al., 2010; Polo et al., 2010; Rizzi et al., 2012). Further 
research is need in order to determine if  these molecular differences affect the 
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potential of  iPS for research or therapeutic applications.
The rationality of  iPS technology came at a high expense: reprogramming 
efficiency is extremely low, ranging from 0.001% to 5% (Kiskinis & Eggan, 2010), 
and transgene integration may lead to oncogenic transformation (Okita et al., 2007). 
Several combinations of  transcription factors, chemicals (e.g. chromatin modifyers, 
kinase inhibitors), microRNAs, donor cells, and non–integrating methods have been 
used to increase reprogramming efficiency and to generate transgene–free iPS cells 
(Yu et al., 2007; Aoi et al., 2008; Ichida et al., 2009; Judson et al., 2009;  Heng et al., 
2010; Kiskinis & Eggan, 2010; Efe & Ding, 2011; Li et al., 2011; Moura, 2011).
The nature of  cellular reprogramming by defined factors seems to be different 
than reprogramming by NT or cell fusion (Jullien et al., 2011). Nuclear remodelling 
by ES cells or oocytes is expected to operate by instructive, deterministic processes 
(Jullien et al., 2011). In contrast, reprogramming by defined factors is stochastic, 
where reversal of  cellular differentiation and induction of  pluripotency occurs in 
random sequences of  events (Hanna et al., 2009; Yamanaka, 2009; Jullien et al., 2011). 
Some somatic cells become trapped in an intermediate reprogramming state, and 
may require additional factors to reach the pluripotent state (Mikkelsen et al., 2008; 
Ichida et al., 2009). The exogenous expression of  reprogramming factors induces 
global chromatin remodelling, induction of  proliferation genes, and repression of  
somatic cell transcriptional program (Mikkelsen et al., 2008; Koche et al., 2011). DNA 
demethylation is a late event in the process of  iPS generation, and occurs in a passive 
manner (Mikkelsen et al., 2008). Moreover, several components of  pluripotency and 
epigenetics machineries have been identified as mediators of  iPS reprogramming 
(Singhal et al., 2010; Maekawa et al., 2011; Onder et al., 2012).
The development of  iPS cells impelled investigations to test if  somatic cells 
could be converted directly to another cell type by defined factors for several reasons. 
Pluripotent cells have important limitations to potential medical applications: 
tumorigenic potential, genetic instability in culture, and current limited understanding 
of  developmental cues to efficiently differentiate ES–iPS in vitro toward specific 
cell types. Cell lineage conversion or transdifferentiation has potential to produce 
unlimited numbers of  disease relevant cells and overcome outlined hurdles associated 
with pluripotency. Neurons, pancreatic β–cells, cardiomyocytes, and other cell types 
have been obtained by direct reprogramming of  development–related cells or readily 
available skin cells (Zhou et al., 2008; Graf  & Enver, 2009; Ieda et al., 2010; Son et 
al., 2011). 
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In a therapeutic perspective, a remarkable example was the direct conversion 
of  pancreatic exocrine cells into β–like cells in vivo and subsequent amelioration 
of  hyperglycaemia in mice (Zhou et al., 2008). Mouse and human fibroblasts were 
also efficiently converted to neurons, and murine neuronal cells recapitulate a 
neurodegenerative disease phenotype in vitro (Son et al., 2011). 
Extensive work has explored several technical difficulties found in reprogramming 
by defined factors: delivery of  reprogramming genes to donor cells, selection of  
reprogramming events, maintainance of  genome integrity, among others. This focus 
on metodological aspects is driven by promising oportunities of  this technology 
for regenerative medicine. However, accumulating evidence is suggesting that direct 
reprogramming will require other improvements in order to produce patient–specific 
differentiated that more closely resemble in vivo counterparts. Further refinements 
will probably emerge from investigations of  the extension of  reprogramming and its 
underlying mechanisms. The stochastic nature of  direct reprogramming represents 
an important roadblock for addressing this phenomenon, and calls for single–cell 
analysis. Integrative genomics of  representative discrete cell populations undergoing 
reprogramming could also be extremely informative (Mikkelsen et al., 2008).   
6. concluSion 
The understanding that development starts from a single cell, and following 
several stepwise, cell fate lineage decisions, builds into complex organisms with 
hundreds of  cell types is a well established concept. From the last century to this 
day, several striking technologies (such as NT, ES cell derivation, and iPS cells) were 
developed based on ingenuous ideas. These new technologies have led to great 
discoveries on how cell fate decisions are made and reversed at the celullar level. 
Molecular analysis of  pluripotency and cellular reprogramming using low resolution 
and genome–wide approaches are expanding our understanding of  these events at 
a very fast pace. However, several technical and biological challenges remain. More 
creativity, and usefull curiosity is needed in order to fully understand these remarkable 
biological processes at the molecular level. 
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